Vaccinex, Inc. announced today that it has been awarded a two-year, $2.0 million grant from the Advanced Technology Program (ATP) of the National Institute of Standards and Technology (NIST). The ATP Program supports highly innovative technologies with the potential for significant economic impact. NIST announced 27 awards today in all areas of high technology. This federal funding will allow expanded applications of Vaccinex’s new library-based antibody discovery technology that may lead to advances in treating cancer, inflammation and infectious diseases. This is the second time Vaccinex has received this prestigious award. The company received a first $2 million ATP award in 2000 for development of its novel technology for the identification of tumor antigens.
